Thrombolytic therapy for acute stroke

It often takes time for a new therapeutic modality to mature into an accepted treatment option. After initial approval, new drugs, devices, and procedures all go through this process until they become "vetted" by the scientific community as well as the medical community at large. Thromboly...

Full description

Saved in:
Bibliographic Details
Other Authors: Lyden, Patrick D. (Editor)
Format: Book
Language:English
Published: Totowa, N.J. Humana Press 2005
Edition:Second Edition
Series:Current clinical neurology
Subjects:
Online Access:Click Here to View Status and Holdings.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000nam a2200000#i 4501
001 wils-335796
005 2023512141548
008 230612t2005 NJU a# #001 deng D
020 # # |a 9781588293985  |q hardback 
020 # # |a 158829398X  |q hardback 
040 # # |a DLC  |d UiTM  |e rda 
041 0 # |a English 
060 0 0 |a WL 355 
090 0 0 |a WL355  |b T5307 2005 
245 0 0 |a Thrombolytic therapy for acute stroke  |c edited by Patrick D. Lyden 
250 # # |a Second Edition 
264 # 1 |a Totowa, N.J.  |b Humana Press  |c 2005 
264 # 4 |c ©2005 
300 # # |a xvii, 370 pages  |b illustrations  |c 24 cm 
336 # # |a text  |b txt  |2 rdacontent 
337 # # |a unmediated  |b n  |2 rdamedia 
338 # # |a volume  |b nc  |2 rdacarrier 
490 1 # |a Current clinical neurology 
504 # # |a Includes bibliographical references and index 
520 # # |a It often takes time for a new therapeutic modality to mature into an accepted treatment option. After initial approval, new drugs, devices, and procedures all go through this process until they become "vetted" by the scientific community as well as the medical community at large. Thrombolysis for treatment of stroke is no exception. Thrombolytic Therapy for Acute Stroke, Second Edition comes four years after the first edition and provides a very comprehensive, updated perspective on the use of intravenous rt-TPA in acute stroke. The authors provide longer term follow-up on the pivotal clinical trials that led to Food and Drug Administration approval, data concerning phase 4 trials in larger numbers of patients, and, most importantly, the community experience that has accumulated since its release. They add to this the latest promising information concerning intra-arterial thrombolysis, which is still under investigation and more speculative sections concerning possible new avenues of clinical research such as combining intravenous thr- bolysis with neuroprotective therapies or intra-arterial thrombolysis. A wealth of factual information is supplemented by chapters containing sage opinion from Drs. Lyden and Caplan concerning the logistical, economic, and procedural issues that have been generated since the advent of this technology. Importantly, diagnosis does not take a back seat to therapeutics as illustrated by sections devoted to eva- ation of the stroke patient, very useful illustrative cases and clinical comments, and chapters on the latest in imaging as applied to this field 
650 1 2 |a Stroke  |x drug therapy 
650 2 2 |a Thrombolytic Therapy 
700 1 # |a Lyden, Patrick D.  |e editor 
856 4 0 |z Click Here to View Status and Holdings.  |u https://opac.uitm.edu.my/opac/detailsPage/detailsHome.jsp?tid=335796 
964 # # |c BOK  |d 01 
998 # # |a 00250##a006.2.2||00250##b006.2.2||00264#1a006.2.2||00264#1b006.2.2||00300##a006.2.2||00300##b006.2.2||00300##c006.2.2||00520##a006.2.2||00520##b006.2.2||